Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.

doi:10.1093/oncolo/oyag158

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.

The oncologist - 6 Jun 2026

Mascaró-Baselga Pau, Rodellar Sanz José Miguel, Nunes da Silva Tiago, Hernando Jorge, García-Álvarez Alejandro, González Merino Carlos, Molina-Cerrillo Javier, Fernandez-Pombo Antia, Iglesias-Alvarez German, Ceballos Lenza Isaac, Plana Serrahima María, Bella Cueto Maria Rosa, Isidro Maria Luisa, Martinez Trufero Javier, Marquina Gloria, Martinez Nieves, Crespo Guillermo, Jimeno Raquel, Lorenzo Isabel, Ayala de Miguel Pablo, Alcazar Victoria, Martínez-Badal Sandra, Capdevila Jaume, Alonso-Gordoa Teresa

Abstract excerpt

BACKGROUND: Anaplastic thyroid cancer (ATC) is an extremely rare cancer with very poor prognosis. Targeted therapies have improved outcomes in selected patients, but molecular testing is often difficult because of the aggressive course, rapid clinical deterioration, and long turnaround times. This study aimed to provide real-world evidence on the management and outcomes of ATC and to evaluate the prognostic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Carcinoma, Anaplastic

Source

Open in PubMed Open full text

Identifiers

PMID: 42179176
DOI: 10.1093/oncolo/oyag158
PMCID: PMC13243708

Genes

BRAF
TERT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.PMID 42179176Read ↗

Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.Semantic proximity Read ↗

Long-term Survivors of Anaplastic Thyroid Cancer: A Genomic Predictive Model.Semantic proximity Read ↗

Clinical actionability of molecular testing in advanced thyroid cancer: a real-world cohort study.Semantic proximity Read ↗

Untitled literature recordSemantic proximity Read ↗

Comprehensive genomic profiling from C-CAT database unveiled over 80% presence of oncogenic drivers in anaplastic thyroid carcinoma including BRAF, RAS family, NF1, and FGFR1.Semantic proximity Read ↗

Personalized treatment of 95 poorly differentiated thyroid cancer/anaplastic thyroid cancer in 2019-2023.Semantic proximity Read ↗

Evaluating new treatments for anaplastic thyroid cancer.Semantic proximity Read ↗

Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma.Semantic proximity Read ↗

Recent advances in anaplastic thyroid cancer management.Semantic proximity Read ↗

NOVEL INSIGHTS IN ADVANCED THYROID CARCINOMA: FROM MECHANISMS TO TREATMENTS: Molecular insights into the origin, biology, and treatment of anaplastic thyroid carcinoma.Semantic proximity Read ↗

Mutation based approaches to the treatment of anaplastic thyroid cancer.Semantic proximity Read ↗

Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.